ViQUAL Medical Technology, a Black-owned biotech company, has officially filed an appeal in its legal battle against Kaiser Permanente, which involves a case valued in the neighborhood of $900 million (according to Law360’s March 22, 2024 article by Marl Karpan in LSIPR – Life Sciences Intellectual Property Review’s publication) to well over $1.5 billion based on estimated profits encompassing years 2012 – 2025 and future projections.
Per George McKinney, CEO of ViQUAL Medical Technology, the appeal alleges serious allegations of misconduct, including the theft of Intellectual Property (IP) and Trade Secrets, as well as corporate exploitation of the legal system to prevent small businesses from achieving their rightful success. The case represents not only a challenge for ViQUAL but also underscores the broader systemic issues faced by Black innovators within the healthcare and biotech sectors.
